Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
TERMINATED
NCT06193421
PHASE1/PHASE2

High-Dose Ambroxol in GBA1-Related Parkinson

Sponsor: Agyany Pharma LTD

View on ClinicalTrials.gov

Summary

Parkinson's disease (PD), affecting 10 million people globally, lacks a cure, and current therapies only manage symptoms. A link between Gaucher disease (GD) and PD, particularly in carriers of glucocerebrosidase (GBA1) mutations, has sparked interest in developing new drugs. Despite pharmaceutical companies focusing on formulations, progress is slow. Agyany, with decades of experience in GD research, plans clinical trials using existing generic drugs for GBA-related PD and idiopathic PD. Their approach targets the misfolded enzyme glucocerebrosidase with pharmacological chaperons, inspired by success in GD using ambroxol. The strategy aims to provide a quicker path to novel therapeutic options for PD.

Official title: An Open-Label Pilot Study for Assessing the Safety and Efficacy of High-Dose Ambroxol (HDA) in Newly Diagnosed GBA1 Parkinson Disease (PD)

Key Details

Gender

All

Age Range

30 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

46

Start Date

2023-10-24

Completion Date

2026-04-30

Last Updated

2026-11-09

Healthy Volunteers

No

Interventions

DRUG

Ambroxol Hydrochloride

75mg slow release (SR), X16/day or 300mg X4/day oral capsules.

Locations (1)

Shaare Zedek Medical Center

Jerusalem, Israel